Increasing with age, dementia will increase its prevalence in the world. One of the best policies to treat and slow the progression of dementia is to diagnose it at its early stage for its less extensively pathological damage of the brain that may lead to a better therapeutic outcome. Meanwhile, different subtypes and stages of dementia have various clinical features, pathological changes, and biomarkers to reflect their specific disease processes. Identifying and capturing these clinical presentations or biomarkers at different stage of dementia are critical to maximize the clinical therapeutic effects.

We are interested in original research articles as well as review articles that explore aspects of screening dementia at its various stages and critical points with its special characteristics, including clinical phenotypes, biomarkers, and psychometrics to reflect the course of dementia.

Potential topics include, but are not limited to:

• Development and testing of novel and effective screening tools to specific type of dementia
• Elucidating the role of a screening tool for its sensitivity, specificity, and positivity
• Predictive value and negative predictive value to various subtypes of dementia
• Identification of biomarkers to the screen of various stages or types of dementia
• Identifying and examining a screening tool in relation to the heterogeneous ethics or cultural background
• Biomarkers or specimens as the screening tools in detecting dementia or reflecting the stage of dementia
• Structure or functional imaging that could reflect or screen dementia